Barb J. Samardzich
Known title: DirectorCIK: 0001183152
Associated companies
Transaction History
| ADNT | ▲ Buy | Grant | 8,208 | — | 3/10/2026 | View on chart |
| ADNT | ▲ Buy | Grant | 10,118 | — | 3/11/2025 | View on chart |
| ADNT | ▲ Buy | Grant | 4,207 | — | 3/12/2024 | View on chart |
| ADNT | ▲ Buy | Grant | 3,312 | — | 3/7/2023 | View on chart |
| ADNT | ▲ Buy | Grant | 4,531 | — | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Adient Q4 Earnings Set for Nov. 4 as Analysts Trim Targets
Adient will report fourth-quarter and full-year fiscal 2026 results on November 4, 2026. Ahead of this announcement, Barclays and UBS both lowered their price targets to $22 and $23, respectively, while maintaining their ratings. Recent commentary also highlights strong backlog growth driven by onshoring initiatives and new customer wins.
Adient Q4 Earnings Set for Nov. 4 as Analysts Trim Targets. Adient will report fourth-quarter and full-year fiscal 2026 results on November 4, 2026. Ahead of this announcement, Barclays and UBS both lowered their price targets to $22 and $23, respectively, while maintaining their ratings. Recent commentary also highlights strong backlog growth driven by onshoring initiatives and new customer wins.